The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

Since Politico reported on the potential selection Thursday afternoon, Pfizer and GSK shares are down about 5%, Sanofi's have ...

French drugmaker Sanofi has revealed the results from the Phase III LUNA 3 trial of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor, in persistent or chronic immune thrombocytopenia (ITP ...

The partnership also allows Sanofi to use the company's adjuvant, Matrix-M, which helps boost the effectiveness of the ...